Relationship between Serum Procalcitonin and microRNA-637 expression among patients with Acute Ischemic Stroke
Abstract
Introduction: Stroke is the second leading cause of death globally, with approximately 80% of all acute strokes being ischaemic. Acute ischaemic stroke (AIS) is a major contributor to disability and mortality worldwide.
Early diagnosis and assessment of stroke severity are vital for timely and effective treatment. MicroRNAs (miRNAs) are small, endogenous, noncoding RNA molecules that regulate gene expression. Procalcitonin
(PCT) and microRNA-637 (miR-637) have been identified as potential biomarkers for AIS. This study aimed to explore the relationship between serum PCT and miR-637 levels in AIS patients.
Objective: To assess the association between serum miR-637 expression and procalcitonin levels in AIS patients.
Methodology: This prospective study included 30 patients diagnosed with AIS within 24 hours of symptom onset. Serum PCT and miR-637 levels were measured using ELISA and qRT-PCR, respectively. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS), and correlation analysis was conducted between PCT, miR-637, and NIHSS scores.
Results: Among 30 AIS patients (18 males, 12 females; mean age 65.8 ± 9.2 years), serum PCT levels were significantly higher in AIS patients compared to healthy controls (0.42 ± 0.28 ng/mL vs. 0.12 ± 0.06 ng/
mL, p < 0.001), while miR-637 levels were significantly lower (0.68 ± 0.32 vs. 1.22 ± 0.41, p < 0.001). Pearson’s correlation analysis showed an inverse relationship between serum PCT and miR-637 (r = -0.72, p < 0.001). Both biomarkers were linked to stroke severity, as indicated by NIHSS scores (PCT: r = 0.58, p = 0.001; miR-637: r = -0.61, p < 0.001).
Conclusion: Elevated PCT and reduced miR-637 levels were associated with higher stroke severity in AIS patients, suggesting their potential as a biomarker panel for stroke diagnosis and severity assessment.
Further studies are needed to confirm these findings.
How to cite this article:
Sanketh S J, Herakal M G, Allichandi R. Serum
Procalcitonin and Serum miR-637 Expression is
Inversely Correlated in Acute Ischaemic Stroke.
J Adv Res Med 2024; 11(2):6-12.
DOI: https://doi.org/10.24321/2349.7181.202403
References
National Centre for Disease Informatics and Research [Internet]. Factsheet: Stroke incidence and mortality:
a report of the population based stroke registries, India; [cited 2023 Dec 24]. Available from https://www.ncdirindia.org/all_reports/pbsrbook/resources/Factsheet.pdf
American Association of Neurological Surgeons [Internet].What is acute ischemic stroke?Neurosurgical
Conditions and Treatments; [cited 2023 Dec 21]. Available from: https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Stroke
Tan JR, Koo YX, Kaur P, Liu F, Armugam A, Wong PT, Jeyaseelan K. microRNAs in stroke pathogenesis. Curr
Mol Med. 2011;11(2):76-92. [PubMed] [Google Scholar]
Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, Turner RJ, Jickling G, Sharp FR. Brain and blood
microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J
Cereb Blood Flow Metab. 2010;30(1):92-101. [PubMed] [Google Scholar]
Zeng L, He X, Wang Y, Tang Y, Zheng C, Cai H, Liu J, Wang Y, Fu Y, Yang GY. MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. Gene Ther. 2014;21(1):37-43. [PubMed]
[Google Scholar]
Walter K. What is acute ischemic stroke? JAMA. 2022;327(9):885. [PubMed] [Google Scholar]
Zhang T, Liu R. Dysregulation of miR-637 serves as a diagnostic biomarker in patients with carotid artery
stenosis and predicts the occurrence of the cerebral ischemic event. Bioengineered. 2021 Dec;12(1):8658-
[PubMed] [Google Scholar]
Feigin VL. Stroke epidemiology in the developing world. Lancet. 2005;365(9478):2160-1. [Google Scholar]
Ramiro L, Simats A, Garcia-Berreocoso T, Montaner J. Inflammatory molecules might become both biomarkers
and therapeutic targets for stroke management. Ther Adv Neurol Disord. 2018;11:175628641878934.
[PubMed] [Google Scholar]
Irime CA, Varciu M, Irimie M, Ifteni PI, Minea DI. C-reactive protein and T3: new prognostic factors
in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2018;27(10):2731-7. [Google Scholar]
Zheng X, Zeng N, Wang A, Zhu Z, Zhong C, Xu T, Xu T, Peng Y, Peng H, Li Q, Ju Z, Geng D, Zhang Y, He J.
Prognostic value of white blood cell in acute ischemic stroke patients. Curr Neurovasc Res. 2018;15(2):151-7.
[PubMed] [Google Scholar]
Bustamante A, Sobrino T, Giralt D, Garcia-Berrocoso T, Llombart V, Ugarriza I, Espadaler M, Rodriguez N,
Sudlow C, Castellanos M, Smith CJ, Rodriguez-Yanez M, Waje-Anderassen U, Tanne D, Oto J, Barber M,
Worthmann H, Wartenberg KE, Becker KJ, Chakraborty B, Oh SH, Whiteley WN, Castillo J, Montaner J.
Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review
and meta-analysis. J Neuroimmunol. 2014;274(1-2):215-24. [PubMed] [Google Scholar]
Aloisio E, Dolci A, Panteghini M. Procalcitonin: between evidence and critical issues. Clin Chim Acta. 2019;496:7-
[PubMed] [Google Scholar]
Katan M, Moon YP, Paik MC, Mueller B, Huber A, Sacco RL, Elkind MS. Procalcitonin and midregional proatrial
natriuretic peptide as markers of ischemic stroke: the northern Manhattan study. Stroke. 2016;47(7):1714-9.
[PubMed] [Google Scholar]
Wang C, Gao L, Zhang ZG, Li YQ, Yang YL, Chang T, Zheng LL, Zhang XY, Man MH, Li LH. Procalcitonin is a
stronger predictor of long-term functional outcome and mortality than high-sensitivity C-reactive protein
in patients with ischemic stroke. Mol Neurobiol. 2016;53(3):1509-17. [PubMed] [Google Scholar]
Rallidis LS, Vikelis M, Panagiotakos DB, Rizos I, Zolindaki MG, Kaliva K, Kremastinos DT. Inflammatory markers
and in-hospital mortality in acute ischaemic stroke. Atherosclerosis. 2006;189(1):193-7. [PubMed] [Google
Scholar]
Chen H, Xie W, He P, Cao Q, Wei D, Zhou H, et al. MicroRNA-637 inhibits the proliferation and metastasis
of colorectal cancer cells by directly targeting Raf kinase inhibitory protein. Mol Med Rep. 2018;17(6):7981-8.
Khoshnam SE, Winlow W, Farbood Y, Moghaddam HF, Farzaneh M. Emerging roles of microRNAs in
ischemic stroke: as possible therapeutic agents. J Stroke. 2017;19(2):166-87. [PubMed] [Google Scholar]
Li J, Wang Y, Wang Y, Zhao X. (2016). Serum procalcitonin levels predict long-term mortality in
patients with acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 25(11), 2752-2758. DOI:
1016/j.jstrokecerebrovasdis.2016.07.01420. Tian D, Zhang S, He X, Liu H. Serum procalcitonin
as a diagnostic marker in acute ischemic stroke. Neuroreport. 2015;26(1):33-7. [PubMed] [Google Scholar]
Xu Y, Zhao L, Liu H, Sun B, Zhao X. Diagnostic value of miR-637 in patients with atherosclerosis and its
predictive significance for the future cardiovascular events. Vascular. 2021 Oct;29(5):704-10. [PubMed]
[Google Scholar]
Li YM, Liu XY. Molecular mechanisms underlying application of serum procalcitonin and stool miR-637
in the prognosis of acute ischemic stroke. Am J Transl Res. 2016 Oct 15;8(10):4242-9. [PubMed] [Google Scholar]
Copyright (c) 2024 SJ Sanketh, M G Herakal, Ravi Allichandi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
